NASDAQ$TSHA
Taysha Gene Therapies Inc · Q1 2026 earnings
Q1 2026 earnings · · Investor relations
Briefing
Taysha reported Q1 2026 with no product revenue, a net loss of $42.4M, and diluted loss per share of $0.12.
The gene-therapy company had no product revenue in Q1 2026 (versus $2.3 million of collaboration revenue a year ago). Net loss was $42.4 million, or $0.12 per diluted share, as R&D rose to $33.8 million. Interest income and fair-value changes on the term loan partially offset operating spend.
- No product revenue; R&D $33.8M.
- Net loss $(42.4)M; diluted EPS $(0.12).
- Share count rose to ~367M basic shares.
- Cash/investments fund CNS gene-therapy programs.
Headline financials
Revenue & EPS history
Taysha Gene Therapies · Revenue · Quarterly
$0
Forward guidance
Clinical milestones for lead programs are the forward indicators; no commercial revenue guidance in the filing.
Tailwinds
- Loss per share stable despite higher R&D.
- Interest income supports net loss trajectory.
- Pipeline focused on monogenic CNS diseases.
Headwinds
- No near-term product sales.
- Clinical/regulatory risk on gene therapies.
- Financing needs if trials expand.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2026
+10.9%
Avg return
Earnings day
+11.7%
Avg return
5 days after
+18.2%
Avg return
30 days after
52%
12 / 23 earnings
Positive
+195.0%
Q2 2023
Best reaction
-16.0%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -3.5% | -6.3% | — | |
| Q1 2026 | +0.6% | -1.6% | -20.9% | |
| Q3 2025 | -5.9% | -8.9% | +18.3% | |
| Q2 2025 | +5.4% | +6.5% | +17.4% | |
| Q1 2025 | +8.1% | +23.6% | +7.2% | |
| Q4 2024 | -4.7% | -4.7% | +13.5% | |
| Q3 2024 | -5.0% | -4.6% | -13.4% | |
| Q2 2024 | +9.1% | +7.7% | +11.0% | |
| Q1 2024 | +29.6% | +28.7% | +73.7% | |
| Q4 2023 | +39.0% | +52.6% | +13.1% | |
| Q3 2023 | +26.3% | +27.8% | +16.5% | |
| Q2 2023 | +195.0% | +159.8% | +312.7% | |
| Q1 2023 | -10.5% | -7.7% | +14.7% | |
| Q4 2022 | -6.5% | +14.8% | -3.9% | |
| Q3 2022 | -5.5% | +9.0% | +2.5% | |
| Q2 2022 | -16.0% | -16.4% | -29.9% | |
| Q1 2022 | -4.1% | -19.5% | -12.5% | |
| Q4 2021 | +3.1% | +8.5% | -40.5% | |
| Q3 2021 | +0.2% | -3.1% | -9.3% | |
| Q2 2021 | +0.7% | -2.6% | +20.1% | |
| Q1 2021 | -0.7% | +2.0% | +19.9% | |
| Q4 2020 | -7.2% | -0.2% | -19.9% | |
| Q3 2020 | +2.2% | +4.0% | +10.3% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro